Not Tagged
Not Tagged
['sclc', 'nsclc']
amivantamab in metex14 skipping nsclc: orr 33%, txnaive orr/pfs 57%/nr, met tki naive orr/pfs 47%/8.3mo and prior met tki orr/pfs 17%/4.2mo novel way to target met, eagerly waiting to see which patients benefit after prior met tkis #asco22 
MD, PhD - Asst Prof, Thoracic Oncology & Precision Medicine Unit Coordinator (CEMIC). Co-Founder PxMedica: https://t.co/6HpAi0RR9P